Success Metrics

Clinical Success Rate
100.0%

Based on 5 completed trials

Completion Rate
100%(5/5)
Active Trials
0(0%)
Results Posted
20%(1 trials)

Phase Distribution

Ph phase_1
4
67%
Ph phase_2
1
17%
Ph phase_3
1
17%

Phase Distribution

4

Early Stage

1

Mid Stage

1

Late Stage

Phase Distribution6 total trials
Phase 1Safety & dosage
4(66.7%)
Phase 2Efficacy & side effects
1(16.7%)
Phase 3Large-scale testing
1(16.7%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

5 of 5 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

6

all time

Status Distribution
Active(1)
Completed(5)

Detailed Status

Completed5
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
0
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 14 (66.7%)
Phase 21 (16.7%)
Phase 31 (16.7%)

Trials by Status

not_yet_recruiting117%
completed583%

Recent Activity

0 active trials
Showing 5 of 6
not_yet_recruitingphase_2

CAIX PET/CT for Residual or Recurrent Post-ablative ccRCC

NCT07077083
completedphase_3

89Zr-TLX250 for PET/CT Imaging of ccRCC- ZIRCON Study

NCT03849118
completedphase_1

Phase I Study to Evaluate the Diagnostic Performance of 89Zirconium Girentuximab PET in Urothelial Cancer Patients

NCT05046665
completedphase_1

Evaluation of 89Zr-TLX250 PET/CT in Chinese Patients With Indeterminate Renal Masses or Suspected Recurrent Renal Clear Cell Carcinoma

NCT05861778
completedphase_1

Evaluation of Safety, Biodistibution and Sensitivity/Specificity of PET/CT Imaging With 89Zr-TLX250 in Subjects With RCC

NCT04496089
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT07077083Phase 2

CAIX PET/CT for Residual or Recurrent Post-ablative ccRCC

Not Yet Recruiting
NCT03849118Phase 3

89Zr-TLX250 for PET/CT Imaging of ccRCC- ZIRCON Study

Completed
NCT05046665Phase 1

Phase I Study to Evaluate the Diagnostic Performance of 89Zirconium Girentuximab PET in Urothelial Cancer Patients

Completed
NCT05861778Phase 1

Evaluation of 89Zr-TLX250 PET/CT in Chinese Patients With Indeterminate Renal Masses or Suspected Recurrent Renal Clear Cell Carcinoma

Completed
NCT04496089Phase 1

Evaluation of Safety, Biodistibution and Sensitivity/Specificity of PET/CT Imaging With 89Zr-TLX250 in Subjects With RCC

Completed
NCT03556046Phase 1

89Zr-girentuximab ) Dosimetry in CCRC Study - ZIR-DOSE

Completed

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6